The Blood Pressure Claim FDA Allows, and Its Price

which blood pressure claims has fda actually issued enforcement discretion for?

FDA has issued exactly three letters of enforcement discretion tying an ingredient to reduced blood pressure risk: magnesium, EPA and DHA together, and calcium. We checked FDA's own Letters of Enforcement Discretion list directly and count three current entries, not the two most compliance summaries cite. Each is a qualified health claim — a claim FDA lets stand despite evidence that falls short of its highest review standard, provided the label says so.

That ceiling exists because FDA's own regulation names hypertension as the textbook disease. Under 21 CFR 101.93(g)(1), a disease is "a state of health leading to such dysfunctioning (e.g., hypertension)" — the parenthetical isn't incidental, it's FDA's own chosen example. A qualified claim is the only legal door left open once a condition is written into the definition of disease itself, rather than left as a symptom you could argue around.

Here's what's actually on the list, and when it landed:

• Sodium and hypertension already have a full health claim, not a qualified one.

what exact disclaimer travels with the epa and dha claim?

The disclaimer is three sentences long, and dropping the third isn't cosmetic. We originally read it, like most compliance one-pagers do, as a two-sentence hedge — until we checked FDA's constituent update directly and found a third sentence requiring an exact gram disclosure. Worth fixing your own reference file if it still shows two.

The first sentence carries the claim itself: FDA's wording states that "consuming EPA and DHA combined may help lower blood pressure in the general population and reduce the risk of hypertension." FDA narrows it immediately in the next sentence: "However, FDA has concluded that the evidence is inconsistent and inconclusive." The third sentence is mechanical rather than rhetorical — it requires stating how many grams of EPA and DHA one serving actually provides, filled in per product, never left as boilerplate.

what dose threshold does the omega-3 claim require per serving?

0.8 grams of combined EPA and DHA per serving is the number that matters. FDA's 2019 update treats this figure as what it calls an enforcement discretion factor — the amount below which the agency said it would not extend discretion — rather than a standalone labeling minimum written into a regulation.

That distinction matters for your formulation, not just your legal file. A single fish-oil softgel commonly falls well under 0.8 grams, which means hitting the threshold often means redefining the serving size as two or three softgels rather than one — a real cost to your bottle count and your per-unit math, decided entirely by you, since no rule specifies a capsule count.

why is 'credible evidence' a different standard from significant scientific agreement?

Because the qualified pathway exists specifically for evidence that doesn't clear FDA's top standard. Significant scientific agreement, the SSA standard behind the twelve health claims FDA has fully authorized, requires something close to consensus across the whole body of public evidence — and none of those twelve cover blood pressure by name. A qualified health claim is what FDA offers instead, when the evidence is real but doesn't reach that bar.

Here's where most marketers read the situation backward: a qualified health claim isn't safer ground than a plain structure/function claim just because FDA's name sits next to it. The disclaimer is a written admission that the evidence fell short of FDA's own top standard, and FTC's substantiation bar runs independently of that claim status — it still expects randomized, controlled human clinical testing before you can advertise the underlying idea at all. Passing FDA's discretion test doesn't pass FTC's.

Blood pressure isn't the only vertical where FDA drew this narrow a line around one ingredient. Chromium picolinate got the same treatment for diabetes, a single compound carrying a single qualified sentence.

The everyday alternative most operators reach for instead is the maintenance framing FDA has separately accepted for cholesterol — trading the disease word for a claim about staying inside a normal range.

can a supplement use the calcium and pregnancy-induced hypertension claim?

Only for the population it was written for: pregnant women, and only for hypertension, pregnancy-induced hypertension, or preeclampsia specifically. FDA issued this letter on October 12, 2005, fourteen years before the omega-3 claim and seventeen before magnesium's, making it the oldest of the three by a wide margin. Nothing on FDA's list extends the claim to general blood pressure management in a non-pregnant adult.

You can't borrow this one for a general audience.

The population half of that fact matters more than most sellers treat it. NHLBI reports that half of all American adults have high blood pressure, and that roughly one in three of those cases go undiagnosed, per NHLBI — a huge, mostly-medicated general audience the calcium claim was never written to reach.

We could not verify a reliable market-size figure for blood pressure supplements specifically this session — no primary NIH or CDC dataset was reachable — and confirming it would mean pulling prevalence and spending data directly from those agencies rather than from an industry landing page.

why did ftc call a 'meets fda qualified health claim' banner deceptive?

Because printing that badge misrepresents what FDA's letter actually decided. FTC's Example 48 describes an advertiser that earned a letter of enforcement discretion for a heart-disease-risk claim and then ran a "Meets FDA Qualified Health Claim" banner; FTC found the banner "mischaracterizes the FDA's action and likely communicates both FDA approval of the product for heart disease and a high level of supporting evidence," per FTC's Health Products Compliance Guidance.

The badge claims what the underlying letter denies.

FDA doesn't approve dietary supplements, and a qualified health claim is FDA saying the evidence is thin enough to require a hedge sentence — the opposite of what a "meets FDA" badge implies to a reader scanning a landing page. The same logic applies to any blood pressure QHC: hold the claim, use its wording, and never advertise the fact that FDA reviewed it.

does holding a qualified claim change what the rest of the funnel can say?

No — a qualified health claim licenses one exact sentence for one ingredient at one dose, and nothing else in your funnel inherits its protection. It says nothing about the testimonial on your landing page, the mechanism story on your blog, or a "for people managing their blood pressure" line in a pre-sell video, and FTC treats each of those as a separate substantiation question.

The FTC has already pursued hypertension advertising claims on their own terms, independent of anything happening at the label level. In its December 2020 CBDeceit sweep the Commission acted against six sellers for unsupported claims about treating serious conditions including cancer, heart disease, hypertension and Alzheimer's disease — proof that a clean claim upstream buys you nothing downstream.

when is the disclaimer cost higher than the claim is worth?

The trade tips against the qualified claim whenever three things line up at once: your formulation can't reliably hit 0.8 grams of combined EPA and DHA without pushing serving size to two or three softgels, your buyer is the general population rather than the pregnant-women audience the calcium claim actually covers, and your media plan depends on testing headlines weekly rather than running one frozen sentence indefinitely. FDA's qualified claims aren't built for creative testing — you can't A/B a disclaimer that has to read "FDA has concluded that the evidence is inconsistent and inconclusive" in full, every time, on every panel. Compare that to what FDA has separately accepted with none of this machinery: a claim about maintaining blood pressure already within a normal range, built on the same maintenance logic the agency took for cholesterol, with no gram disclosure, no fixed sentence, and no exposure to an FTC complaint over a badge you never actually earned to display.

The same one-word economics show up again in sleep supplements, where the entire safe harbor rests on a single approved adverb instead of a three-sentence disclaimer.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, A Cavity Claim Makes It an Unapproved OTC Drug, 'Promotes Low Blood Pressure' Is Already a Drug Claim, "Occasional" Is the Word Holding Heartburn Copy Up, Two RCTs or Nothing: What FTC Orders Leave Behind, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.